NEWS SEARCH ANALYSIS INSIGHT

360° SearchNetwork Hot Spots Trends

Advanced Search Options >>

Saturday, November 21, 2009 4:58 AM

Biogen Idec

Type: Company

Name: Biogen Idec

Nationality: United States

Web Address: http://www.biogenidec.com/

Fact Sheet: Fact Sheet for Biogen Idec

First Reported 11 hours ago - Updated 8 hours ago - 3 Documents

UPDATE 2-HealthCor slams Biogen CEO for outsize pay package

* HealthCor criticizes Biogen CEO paycheck, stock sales * Calls on company to initiate sustained buyback program * Says company should cut R&D expenses (Updates with company comment, share price) By Toni Clarke BOSTON, Nov 20 (Reuters) - Biogen ... [Economy-Finance - 8 hours ago]

Entities: James Mullen, Tysabri, Biogen Idec

First Reported 11/19/2009 - Updated 11/19/2009 - 2 Documents (in Medicine)

Genentech Inc

Genentech, Biogen Idec receive complete response for cancer drug application

SOUTH SAN FRANCISCO, Calif. (Nov. 19) The Food and Drug Administration has turned down a request by two biotech companies seeking approval for a drug as a treatment for chronic lymphocytic leukemia.Biogen Idec and Genentech, now part of Switzerland-based ... [Drug Store News - 11/19/2009]

Entities: complete response, Biogen Idec, Genentech Inc

First Reported 11/19/2009 - Updated 11/19/2009 - 2 Documents (in Health)

Pfizer Inc

Cancer Therapies - Global Market Opportunities

Dublin - Research and Markets (http://www.researchandmarkets.com/research/3a45c7/cancer-therapies) has announced the addition of the ' ' report to their offering.Cancer therapies are geared towards controlling the growth of cancerous tumors, and preventing ... [Pharmacy Choice - 11/19/2009]

Entities: United States, Pfizer Inc, Abraxis BioScience Inc, Roche Holding Ltd

First Reported 11/19/2009 - Updated 11/19/2009 - 1 Documents (in Biology)

Biogen Idec, Inc. (Massachusetts) (BIIB)'s (JOBS) Tysabri, the MS Drug Haunted by Deadly Side Effect, Doesn't Look So Deadly Anymore

Xconomy.com -- Few doctors knew much about a rare brain infection called PML back in 2005, when two patients on a hot new multiple sclerosis drug from Biogen Idec and Elan died from the side effect. The infection, at the time, was generally considered ... [BioSpace - 11/19/2009]

Entities: Tysabri, Biogen Idec, Side Effect

First Reported 11/19/2009 - Updated 11/19/2009 - 1 Documents

Food and Drug Administration

FDA Clears Way for Use of Rituxan for Leukemia

The FDA has approved Genentech and Biogen Idec’s Rituxan plus chemotherapy for patients with untreated chronic lymphocytic leukemia (CLL), openingup a new market for the pharmaceutical. ... [FDA News - 11/19/2009]

Entities: Rituxan, Leukaemia, Food and Drug Administration

First Reported 11/19/2009 - Updated 11/19/2009 - 1 Documents

Novartis AG

Swiss stocks - Factors to watch on Nov 19

SWATCH GROUP (UHR.VX), RICHEMONT (CFR.VX)Watch export data due at 0715 GMTROCHE, NOVARTIS (ROG.VX)(NOVN.VX)* Roche and Novartis's asthma drug Xolair should not be approved for children aged 6 to 11, a U.S. advisory panel decided on Wednesday.* Roche unit ... [Reuters UK - 11/19/2009]

Entities: Food and Drug Administration, Novartis AG, Omalizumab, Rituxan, chronic lymphocytic leukemia

First Reported 8 hours ago - Updated 8 hours ago - 1 Documents

Biogen shareholders: CEO pay 'inconsistent' with poor stock performance

One of Biogen Idec Inc.’s largest investors is criticizing CEO James Mullen’s compensation package and other corporate spending initiatives in an effort to goad the company into boosting its stock performance. ... [Mass High Tech - 8 hours ago]

Entities: James Mullen, Biogen Idec, Induction

First Reported 1 hour ago - Updated 1 hour ago - 1 Documents (in Medicine)

Genentech & Biogen Idec get complete response letter from US FDA for Rituxan to treat CLL

Genentech, Inc, a wholly-owned member of the Roche Group and Biogen Idec announced that the US Food and Drug Administration (FDA) issued a complete response on the companies' applications for Rituxan (rituximab) plus fludarabine and cyclophosphamide (FC) ... [PharmaBiz - 1 hour ago]

Entities: Rituxan, Biogen Idec, Genentech Inc, complete response, Food and Drug Administration

First Reported 11/18/2009 - Updated 11/18/2009 - 2 Documents (in Corporate Deals)

Business in brief: MS wonder drug 'balanced alert'

Elan and partner Biogen Idec aim to find a 'balanced way' of alerting investors about the number of brain infections linked to their Tysabri multiple sclerosis drug by the end of this year after a surge in cases, CEO Kelly Martin said yesterday. It was ... [Irish Independent - 11/18/2009]

Entities: Multiple Sclerosis, Kenneth Jacobs, Tysabri

First Reported 11/16/2009 - Updated 11/16/2009 - 1 Documents (in Biology)

Research and Markets: Best Practices for Internal Communications Regarding Brands & Disease States

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/c594e8/best_practices_for) has announced the addition of the "Best Practices for Internal Communications Regarding Brands & Disease States" report to their offe ... [Business Wire UK - 11/16/2009]

Entities: Induction, Benchmarking, Biotechnology, Jazz Pharmaceuticals Inc

First Reported 11/17/2009 - Updated 11/17/2009 - 1 Documents (in Biology)

Report on best practices for internal communications regarding brands & disease states

This benchmarking study, based on benchmark survey data and executive interviews of 45 participants from more than 34 leading pharmaceutical, biotechnology and medical device companies, was conducted to examines the programs and initiatives aimed at directly ... [News-Medical.Net - 11/17/2009]

Entities: Induction, Benchmarking, Biotechnology, Organon B V

First Reported 11/18/2009 - Updated 11/18/2009 - 1 Documents (in Conflicts & Crime)

Activity Jumps in Biotech and Drug Firms

Activity in Biogen Idec jumped to twice the normal level, after traders elected to sell 'straddles' in the firm's options. ... [WSJ.com: Markets - 11/18/2009]

Entities: Biotechnology, Biogen Idec

Quotes

"James Mullen has made considerable personal profits while running Biogen Idec and has egregiously continued to sell down his personal holdings in the Company, while investors have been left holding the bag" HealthCor wrote in its letter

UPDATE 1-HealthCor slams Biogen CEO for outsize pay package [Forbes.com - 10 hours ago]

"This would contribute approximately $1 per share in EPS, which at Biogen Idec's current 2010 [price-to-earnings] multiple would be worth $10 per share to the stock price" HealthCor wrote

HealthCor Urges Biogen Board Consider Number Of Changes [Nasdaq - 11 hours ago]

...& Company, a San Francisco based global leader in life sciences with activities in Private Equity, Venture Capital, Merchant Banking and Media. "The nervousness about the strength of the economic recovery combined with weaker or average financial results took its toll on biotech's top companies. "However, it wasn't just biotech's elite companies that took a hit. With investors nervous about the economy they have taking profits and cashing in on the excellent gains made by emerging biotech companies and, as a result, the Burrill Biotech Mid-Cap Index fell a whopping 18 percent and Burrill Biotech Small Cap Index was down 15 percent for the month. "There has also been some investor uncertainty over the healthcare reform debate and this is likely to continue, as the legislators wade through the proposals," commented Burrill. "The drug industry certainly will take a big hit in the House bill, which was released by the Democrats at the end of the month. For elderly people who are eligible for both Medicare and Medicaid, the bill mandates rebates from the drug makers so that the Medicare system ends up paying less. Those rebates are estimated to cost the industry $60 billion over a decade. "The bill is in favor of allowing 12 years of data exclusivity for biotech drugs and that is good for our industry," concluded Burrill. "It is clear that there will be plenty of debate in the upcoming month as legislators try and get the healthcare reform bill passed before the end of the year. With 25-50 million Americans added to the healthcare system, revenues for the healthcare industry should increase... so the bills are a mixed bag for pharma, med devices and biotechs." (c) 2009 Cancer Weekly via Rx.com Pharmacy Index Front Page Healthcare LIVE ONLINE CE Nov 12: Nov 16: Nov 17: Nov 18: Nov 19: Special Announcement Free Membership to register to Win an iPod nano. Enjoy , , and more... Nursing Jobs Are you a nurse looking for a job? Check out the . Your number one choice for nursing jobs. Websites » • • • • • • • Front Page Healthcare Jobs Placement s FDA Pharmacy letters Continuing MOST POPULAR Continuing FDA Pharmacy Copyright © 2009 Pharmacy Choice - All rights reserved. 888-682-4415"

Biotech Takes It on the Chin in October [Pharmacy Choice - 11/13/2009]

More Content

sort by: Date \| Relevance
Genentech & Biogen Idec get complete respon... [PharmaBiz - 1 hour ago]
US midday: Tech and house builders lead market ... [Digital Look - 7 hours ago]
Biogen shareholders: CEO pay 'inconsistent' wit... [Mass High Tech - 8 hours ago]
Biogen Idec Accused Again of Excessive CEO Pay,... [Xconomy - 9 hours ago]
UPDATE 1-HealthCor slams Biogen CEO for outsize... [Forbes.com - 10 hours ago]
HealthCor Urges Biogen Board Consider Number Of... [Nasdaq - 11 hours ago]
ImmunoGen, Inc. Announces Second License Taken ... [Freshnews.com - 11/20/2009]
FDA Clears Way for Use of Rituxan for Leukemia [FDA News - 11/19/2009]
Biogen Idec, Inc. (Massachusetts) (BIIB)'s (JOB... [BioSpace - 11/19/2009]
ImmunoGen, Inc. Announces Second License Taken ... [Business Wire via MSN Money - 11/19/2009]
ImmunoGen, Inc. Announces Second License Taken ... [Stockwatch - 11/19/2009]
This Stock Is a Train Wreck [Motley Fool - 11/19/2009]
Read the rest of the story [Mass High Tech - 11/19/2009]
Tech philanthropy brings wave of contributions,... [Mass High Tech - 11/19/2009]
Industry, government, academia make work force ... [Mass High Tech - 11/19/2009]
Cancer Therapies - Global Market Opportunities [Pharmacy Choice - 11/19/2009]
Genentech, Biogen Idec receive complete respons... [Drug Store News - 11/19/2009]
Genentech, Biogen Idec cancer drug rejected [Drug Store News - 11/19/2009]
Research and Markets: Cancer Therapies - Global... [Business Wire UK - 11/19/2009]
No Relief for Genzyme as APB Failure Dents Rena... [BioWorld - 11/19/2009]
FDA issues complete response for Rituxan, a dru... [News-Medical.Net - 11/19/2009]
Swiss stocks - Factors to watch on Nov 19 [Reuters UK - 11/19/2009]
Genentech, Biogen Idec Gets Complete Response F... [RTTNews.com - 11/18/2009]
BRIEF-Genentech and Biogen get FDA complete res... [Forbes.com - 11/18/2009]
BRIEF-Genentech and Biogen get FDA complete res... [Interactive Investor International - 11/18/2009]
Genentech and Biogen Idec Receive a Complete Re... [Business Wire - 11/18/2009]
www.Xtremepicks.Com: Xtremepicks Alerts Novembe... [TMC Net - 11/18/2009]
Research and Markets: Uncovering Biomarker and ... [Forbes.com - 11/18/2009]
Alnylam Presents New Pre-clinical Data on ALN-V... [Earthtimes.org - 11/18/2009]
Alnylam Presents New Pre-clinical Data on ALN-V... [RBC Dain Rauscher - 11/18/2009]

Blogs

sort by: Date \| Relevance
UPDATE 2-HealthCor slams Biogen CEO for outsize... [Economy-Finance - 8 hours ago] * HealthCor criticizes Biogen CEO paycheck, stock sales * Calls on company to initiate sustained buyback program * Says company should cut R&D expenses (Updates ...
Merck’s Dick Clark Has Opportunities, but All A... [WSJ.com: Deal Journal - 11/16/2009] Jacob Plieth, of Dow Jones Investment Banker, reports: So Richard Clark is on the hunt. The Merck CEO said early this month that he is looking to acquire biotechnology ...
PanGenetics Sells PG110 to Abbott [alarm:clock euro - 11/13/2009] PanGenetics, a therapeutic antibody development company with offices in UK and Netherlands has agreed to sell PG110 to Abbott, which will market this antibody ...
Top 10 Analyst Upgrades, Downgrades, Initiation... [24/7 Wall St. - 11/02/2009] These are this Monday’s top ten analyst upgrades, downgrades, and initiations seen from Wall Street research firms: Biogen Idec (NASDAQ: BIIB) Raised to Buy at ...
The Role of the Washington DC District Court in... [Patent Law Blog (Patently-O) - 10/22/2009] Stuart Soffer has provided information on an interesting spike in patent litigation filings in the Washington DC Federal District Court (DDC). As the chart below ...

Audio/Video

sort by: Date \| Relevance
Wall Street Journal's What's News Late Edition,... [Wall Street Journal What's News - 06/03/2009]

Change Password

Log in to Silobreaker

Advanced Search Options

Biogen Idec